Opus Genetics reported second quarter collaboration revenue of $0.8 million and a net loss of $8.1 million, or ($0.08) per share. The clinical-stage biopharmaceutical company provided key updates on its gene therapy pipeline and ended the quarter with a strong cash position.
Key Highlights
- Cash and cash equivalents of $88.8 million are expected to fund operations into 2029.
- Topline data from Cohort 1 of the Phase 1/2 OPGx-BEST1 trial is anticipated in the second week of September 2026.
- Enrollment for the registrational Phase 3 trial of OPGx-LCA5 is now complete, with patient dosing planned for the fourth quarter of 2026.
- Research and Development expenses nearly doubled to $11.2 million from $6.0 million year-over-year, driven by increased manufacturing and clinical costs for its inherited retinal disease programs.